Publications by authors named "S D Vasikaran"
Guidelines for the correct use of the nomenclature of biochemical indices of bone status: a position statement of the Joint IOF Working Group and IFCC Committee on Bone Metabolism.
Giovanni Lombardi Niklas Rye Jørgensen Nicholas C Harvey Eugene V McCloskey Kristina E Åkesson Samuel D Vasikaran
Clin Chem Lab Med
November 2024
Article Synopsis
- - The guidelines update the International Osteoporosis Foundation's (IOF) 20-year-old position paper on bone markers, reflecting advancements in bone biology and disorders.
- - The authors introduce a new classification called Bone Status Indices (BSI) to replace outdated terms like bone turnover markers and metabolic markers for better clarity.
- - The proposal includes standardized nomenclature, abbreviations, and measurement units for these indices to ensure consistency in the study and treatment of bone health.
Advances in assessment and treatment of bone, mineral and parathyroid disorders.
Curr Opin Endocrinol Diabetes Obes
August 2024
Reference intervals for CTX and P1NP in a multi-ethnic Malaysian cohort.
Malays J Pathol
December 2023
Background: Well defined reference intervals are central to the utility of serum C-terminal telopeptide of type 1 collagen (CTX) and N-terminal propeptide of type I procollagen (P1NP), designated as reference markers in osteoporosis, and useful for monitoring therapeutic response in that condition. This study reports the reference intervals for plasma CTX and serum P1NP in a multi-ethnic Malaysian population.
Methods: Ethnic Malay, Chinese or Indian subjects aged 45-90 years old were recruited from Selangor, Malaysia from June 2016 to August 2018.
Article Synopsis
- - Bone-turnover markers (BTMs) are important for reflecting bone remodeling rates and managing metabolic bone diseases, with increasing evidence and guidelines supporting their diagnostic use, particularly in populations from the Asia-Pacific region.
- - Key BTMs, like procollagen I N-terminal propeptide and β-isomerized C-terminal telopeptide, are critical for diagnosing osteoporosis, backed by specific reference intervals and targets tailored for premenopausal women in these populations.
- - For patients with advanced chronic kidney disease, using BTMs that aren't affected by renal failure could be beneficial; further research and standardization of tests are needed for better clinical outcomes.